N Lawrence Edwards

Summary

Affiliation: University of Florida
Country: USA

Publications

  1. ncbi request reprint Emerging therapies for gout
    N Lawrence Edwards
    Department of Medicine, University of Florida College of Medicine, 1600 South West Archer Road, Gainesville, FL 32610 0277, USA Electronic address
    Rheum Dis Clin North Am 40:375-87. 2014
  2. doi request reprint Quality of care in patients with gout: why is management suboptimal and what can be done about it?
    N Lawrence Edwards
    Division of Rheumatology, University of Florida, 1600 Southwest Archer Road, Room 4102, Gainesville, FL 32610 0277, USA
    Curr Rheumatol Rep 13:154-9. 2011
  3. doi request reprint Febuxostat: a new treatment for hyperuricaemia in gout
    N Lawrence Edwards
    Department of Medicine, University of Florida, Gainesville, FL 32610, USA
    Rheumatology (Oxford) 48:ii15-ii19. 2009
  4. doi request reprint The role of hyperuricemia in vascular disorders
    N Lawrence Edwards
    Department of Medicine, University of Florida, Gainesville, 32610 0221, USA
    Curr Opin Rheumatol 21:132-7. 2009
  5. ncbi request reprint The role of hyperuricemia and gout in kidney and cardiovascular disease
    N Lawrence Edwards
    Department of Medicine, University of Florida, Gainesville, 32610 0221, USA
    Cleve Clin J Med 75:S13-6. 2008
  6. ncbi request reprint Case 9: initiation of urate-lowering therapy for advanced gout complicated by chronic renal insufficiency
    N Lawrence Edwards
    Department of Medicine, University of Florida, Gainesville, Florida, USA
    Am J Med 119:S29-31. 2006
  7. doi request reprint Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout
    William J Taylor
    From the Department of Medicine, University of Otago, Wellington, New Zealand Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA Department of Medicine, University of Auckland, Auckland, New Zealand University of Pennsylvania and Veterans Affairs VA Medical Center, Philadelphia, Pennsylvania, USA Department of Medicine, University of Florida, Gainesville, Florida, USA SDG LLC, Cambridge, Massachusetts, USA and Integrated Hospital Care Franchise, Immunology, Novartis Pharma AG, Basel, Switzerland Pfizer Inc, New York, New York, USA Epidemiology, Merck Sharp and Dohme Corp, Whitehouse Station, New Jersey, USA Clinical Sciences, Regeneron Pharmaceuticals, Tarrytown, New Jersey, USA Health and Rehabilitation Research Institute and School of Podiatry, Auckland University of Technology, Auckland, New Zealand and Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA
    J Rheumatol 41:574-80. 2014
  8. pmc Patient-reported outcomes in chronic gout: a report from OMERACT 10
    Jasvinder A Singh
    Medicine Service, Birmingham Veterans Affairs VA Medical Center and Division of Rheumatology, Department of Medicine, University of Alabama, Birmingham, AL 35294, USA
    J Rheumatol 38:1452-7. 2011
  9. ncbi request reprint Pain management in gout
    Brian S Kirby
    Curr Pain Headache Rep 12:418-22. 2008
  10. ncbi request reprint Treatment of osteoarthritis
    Elena V Barnes
    Division of Rheumatology, Department of Medicine, University of Florida, Gainesville 32610, USA
    South Med J 98:205-9. 2005

Detail Information

Publications14

  1. ncbi request reprint Emerging therapies for gout
    N Lawrence Edwards
    Department of Medicine, University of Florida College of Medicine, 1600 South West Archer Road, Gainesville, FL 32610 0277, USA Electronic address
    Rheum Dis Clin North Am 40:375-87. 2014
    ..The historic shortcomings of current gout treatment may, in part, be overcome by these novel approaches. ..
  2. doi request reprint Quality of care in patients with gout: why is management suboptimal and what can be done about it?
    N Lawrence Edwards
    Division of Rheumatology, University of Florida, 1600 Southwest Archer Road, Room 4102, Gainesville, FL 32610 0277, USA
    Curr Rheumatol Rep 13:154-9. 2011
    ..Widespread education about evidence-based diagnostic and treatment guidelines is desperately needed...
  3. doi request reprint Febuxostat: a new treatment for hyperuricaemia in gout
    N Lawrence Edwards
    Department of Medicine, University of Florida, Gainesville, FL 32610, USA
    Rheumatology (Oxford) 48:ii15-ii19. 2009
    ..In conclusion, febuxostat is more effective than allopurinol 300 mg daily in reducing sUA levels <6 mg/dl (360 mumol/l), the target recommended by EULAR, and offers a new option for the long-term treatment of gout...
  4. doi request reprint The role of hyperuricemia in vascular disorders
    N Lawrence Edwards
    Department of Medicine, University of Florida, Gainesville, 32610 0221, USA
    Curr Opin Rheumatol 21:132-7. 2009
    ..Others have viewed it as an important antioxidant. These opinions have given way to strong epidemiologic evidence that uric acid elevation may damage endothelial cells and cause significant medical problems...
  5. ncbi request reprint The role of hyperuricemia and gout in kidney and cardiovascular disease
    N Lawrence Edwards
    Department of Medicine, University of Florida, Gainesville, 32610 0221, USA
    Cleve Clin J Med 75:S13-6. 2008
    ..Additional animal studies and recent epidemiologic findings have provided further evidence that soluble urate is a risk factor for nonarticular disease...
  6. ncbi request reprint Case 9: initiation of urate-lowering therapy for advanced gout complicated by chronic renal insufficiency
    N Lawrence Edwards
    Department of Medicine, University of Florida, Gainesville, Florida, USA
    Am J Med 119:S29-31. 2006
  7. doi request reprint Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout
    William J Taylor
    From the Department of Medicine, University of Otago, Wellington, New Zealand Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA Department of Medicine, University of Auckland, Auckland, New Zealand University of Pennsylvania and Veterans Affairs VA Medical Center, Philadelphia, Pennsylvania, USA Department of Medicine, University of Florida, Gainesville, Florida, USA SDG LLC, Cambridge, Massachusetts, USA and Integrated Hospital Care Franchise, Immunology, Novartis Pharma AG, Basel, Switzerland Pfizer Inc, New York, New York, USA Epidemiology, Merck Sharp and Dohme Corp, Whitehouse Station, New Jersey, USA Clinical Sciences, Regeneron Pharmaceuticals, Tarrytown, New Jersey, USA Health and Rehabilitation Research Institute and School of Podiatry, Auckland University of Technology, Auckland, New Zealand and Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA
    J Rheumatol 41:574-80. 2014
    ..To determine the extent to which instruments that measure core outcome domains in acute gout fulfill the Outcome Measures in Rheumatology (OMERACT) filter requirements of truth, discrimination, and feasibility...
  8. pmc Patient-reported outcomes in chronic gout: a report from OMERACT 10
    Jasvinder A Singh
    Medicine Service, Birmingham Veterans Affairs VA Medical Center and Division of Rheumatology, Department of Medicine, University of Alabama, Birmingham, AL 35294, USA
    J Rheumatol 38:1452-7. 2011
    ..To summarize the endorsement of measures of patient-reported outcome (PRO) domains in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10)...
  9. ncbi request reprint Pain management in gout
    Brian S Kirby
    Curr Pain Headache Rep 12:418-22. 2008
    ..This article addresses the epidemiology, inflammatory pathophysiology, pain management techniques (including recent advances), and treatment of the underlying disease itself...
  10. ncbi request reprint Treatment of osteoarthritis
    Elena V Barnes
    Division of Rheumatology, Department of Medicine, University of Florida, Gainesville 32610, USA
    South Med J 98:205-9. 2005
    ..Presently, there are no proven structure/disease-modifying interventions and therefore current therapy is aimed to symptom relief and rehabilitation...
  11. ncbi request reprint Case 6: maintenance therapy for simple intermittent gout
    N Lawrence Edwards
    Department of Medicine, University of Florida, Gainesville, Florida, USA
    Am J Med 119:S20-2. 2006
  12. doi request reprint OMERACT endorsement of measures of outcome for studies of acute gout
    Jasvinder A Singh
    From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA Department of Medicine, University of Otago, Wellington Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand SDG LLC, Cambridge, Massachusetts, Duke University School of Medicine, Durham, North Carolina, USA, and Duke National University of Singapore Graduate Medical School, Singapore Schlosspark Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA University of Ottawa, London, Ontario, Canada University of Michigan Medical School, Ann Arbor, Michigan, USA University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA Maastricht University Medical Center, Division of Rheumatology, and CAPHRI Research Institute, University Maastricht VU University Medical Center, Amsterdam, the Netherlands University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Service de Neurochirurgie
    J Rheumatol 41:569-73. 2014
    ....
  13. ncbi request reprint Outcome evaluations in gout
    H Ralph Schumacher
    Division of Rheumatology, University of Pennsylvania School of Medicine, and Veterans Affairs Medical Center, Philadelphia, Pennsylvania 19104, USA
    J Rheumatol 34:1381-5. 2007
    ..Final validation of these outcomes has not yet been achieved. In summary, the unique problems of evaluating outcomes in gout are finally being addressed. While no measures are available for use yet, an agenda has been developed...
  14. ncbi request reprint Case 7: differential diagnosis of advanced gout
    N Lawrence Edwards
    Department of Medicine, University of Florida, Gainesville, Florida, USA
    Am J Med 119:S23-4. 2006